Main Menu

The technology is a novel antibody test designed for the detection of Mycoplasma antibodies, representing a significant advancement in Mycoplasma detection methods. This test offers a rapid and reliable means of diagnosing Mycoplasma infections, which is particularly valuable in research and clinical settings. Unlike existing tests, this innovative approach provides specificity and sensitivity in detecting Mycoplasma antibodies, ensuring accurate and timely diagnosis.

Summary:

The National Cancer Institute (NCI) sees research co-development partners and/or licensees for an automated acoustophoresis device to radio-label and isolate cells.

This technology includes improvements in the fluorescence scanner to increase efficiency. This method works by eliminating the need to radially slide the optical assembly during scanning, instead using a galvanometric mirror deflecting a laser beam to different positions in the sample. This allows the scanner to be incorporated into existing commercial analytical ultracentrifugation (AUC) systems with minimal modifications.

Summary:

We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology.

Description of Technology:

There is growing awareness that a wide variety of synthetic and natural compounds that may be present in water sources, such as streams, wells, and ground water, may lead to adverse health effects, including increased cancer risk. Even low concentrations of these compounds are of concern, as they may have biological effects at concentrations of parts per billion or less.

Summary:

The NCI seeks research co-development partners and/or licensees for a biomarker analysis software for high-throughput diagnostic multiplex data.

Summary:

The inventors are constructing a prototype system and seek licensing or co-development opportunities from commercial flow cytometry platforms to optimize the invention for use in combination with their proprietary platforms.

Summary:

Researchers at NCI seek licensing and/or co-development research collaborations for further development of the Bacteriophage based-vaccine system.

Summary:

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T-cell receptors (TCRs) that specifically target the mutated KRAS antigen.

Summary:

The NCI is seeking licensees to develop an automated digital pathology device compatible with high-throughput data analysis.